Cargando…
Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
Autores principales: | Juneja, Kavita, Humeniuk, Rita, Porter, Danielle, Cao, Huyen, Feng, Joy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097414/ https://www.ncbi.nlm.nih.gov/pubmed/33558289 http://dx.doi.org/10.1128/AAC.00085-21 |
Ejemplares similares
-
Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021) -
Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021) -
Author's Reply: Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?
por: Suzuki, Soichiro, et al.
Publicado: (2019) -
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
por: Humeniuk, Rita, et al.
Publicado: (2021) -
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)